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100% and 95% motion, where 100% is the peak-to-peak 
motion. The 95% is defined as the bandwidth that includes 
95% of the data points but excludes the 5th percentile most 
extreme data points. 
Results: The two MRI scans were obtained with a mean 
interval of 16 days (range 0-37 days). All patients tolerated 
the corset well during MRI scanning and radiotherapy. Motion 
characteristics are described in Table 1. Peak-to-peak motion 
without corset in craniocaudal direction was on average 11.3 
mm, with a maximum amplitude of 22.1 mm. With the 
application of the corset, the average 100% craniocaudal 
motion was 7.3 mm (maximum amplitude 13.4 mm). The 
largest decrease in 100% motion was seen in craniocaudal 
direction, with an average reduction of 4.1 mm. In lateral 
direction, a decrease in 100% motion of 0.4 mm was 
observed. In anteroposterior direction, no motion reduction 
was seen. The largest motion reduction achieved in one 
patient was a 100% motion of 22.1 mm without corset; with 
the corset this was 4.9 mm. A typical example of tumor 




Conclusions: Substantial pancreatic tumor motion decrease 
was observed with the use of a custom abdominal corset. As 
a result, treatment margin reduction is possible for 
stereotactic radiotherapy in free breathing conditions with 
maintained patient comfort. This in turn offers opportunities 
for dose escalation without increasing toxicity. 
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Purpose/Objective: MLC tracking is a promising method for 
real-time target motion compensation by continuous 
adaptation of the MLC aperture to a moving target. A number 
of studies with proto-type MLC tracking systems have 
demonstrated the ability to mitigate motion-induced dose 
errors, and a non-commercial system is currently used in a 
clinical study of prostate cancer. However, to get MLC 
tracking into routine clinical practice at a larger scale a more 
integrated system is needed. This study provides the first 
characterization of the prototype MLC tracking system 
included in the research part of the Varian TrueBeam 2.0 
accelerator. 
Materials and Methods: Several experiments were performed 
to characterize the performance of Calypso-guided MLC 
tracking on a TrueBeam linear accelerator. The MLC tracking 
system latency was determined as the time lag between 
sinusoidal target motion and the center of a circular beam as 
recorded by continuous MV portal imaging during MLC 
tracking with prediction turned off. Normally, the jaws also 
follow the target just outside the MLC aperture. The tracking 
latency of the backup jaws was determined similarly in portal 
images by tracking a rectangular field formed by the jaws 
alone. The geometric tracking accuracy was determined as 
the 2D distance in portal images between a target following 
eight representative trajectories (prostate and lung) and the 
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circular MLC aperture. The dosimetric tracking accuracy was 
quantified by measuring the dose of low and high modulation 
VMAT plans to a moving Delta4PT phantom that reproduced 
the same eight trajectories and comparing this dose with a 
static reference dose (2%/2mm gamma evaluation). A linear 
Kalman filter prediction was used to account for the tracking 
system latency in the geometric and dosimetric accuracy 
experiments. 
Results: The mean tracking system latency was 145ms 
(SD=7.4ms) for MLC tracking and 143ms (SD=17ms) for the 
tracking backup jaws. Compared to non-tracking, MLC 
tracking reduced the mean root-mean-square geometric 
targeting error from 2.7mm to 0.5mm (parallel to MLC 
leaves) and from 2.4mm to 1.1mm (perpendicular). 
Dosimetrically, MLC tracking reduced the motion induced 
gamma failure rate from 30.0% to 9.4% (prostate) and from 
41.2% to 3.4% (lung) on average (see Table). 
Conclusions: TrueBeam MLC tracking performance was 
thoroughly investigated for the first time. The system has 
similar geometric and dosimetric performance as previously 
reported for prototype MLC tracking systems. The inclusion of 
backup jaw tracking effectively reduces radiation outside the 
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Purpose/Objective: Weight loss is common during head and 
neck (HN) radiotherapy, often resulting in reduced plan 
quality relative to that intended. At this institution ART is 
performed only when necessary, and patients are monitored 
for anatomic changes through weekly CBCT imaging. If 
radiographers suspect that observed weight loss might be 
significant, the patient images are referred to physics for 
dosimetric review. This process is time consuming, and only a 
small number of reviews reveal clinically significant 
dosimetric changes. The decision to refer a patient for 
dosimetric review is highly subjective, and with the 
implementation of ART likely to increase in the future, there 
is a need for tools that introduce objectivity into this 
process. A simple contour-based tool, which creates a 
patient-specific contour that can be used to objectively 
assess weight loss, is presented. 
Materials and Methods: An individualised patient contour, 
created by contracting the external patient contour by 
distances depending on the control point weighting in the 
VMAT plan, was created using an in-house Python script. An 
additional uniform contraction of the external contour was 
also created to serve as a baseline for comparison. These ART 
contours were created for ten patients and applied to on-
treatment CBCT images that had been previously analysed 
due to observed weight loss during treatment. The patient 
contour was outlined on the CBCT images and the area of 
overlap with the different ART contours was recorded. This 
area of overlap was then compared with changes in mean 
dose to PTVs, and changes in maximum doses to 1 cm3 (1 cc 
max) for the spinal cord (SC) and brainstem (BS). The 
correlation between the area of overlap and change in 
dosimetric parameters was then measured to determine 
whether the individualised contour could predict the 
dosimetric effects of weight loss. 
Results: The area of overlap for both contour typescorrelated 
with the change in mean dose to the targets and the change 
in 1 cc max for the SC and BS, as shown in the table. With 
the exception of PTV1 mean dose, which showed moderate 
correlation for both contour types, all dosimetric parameters 
showed a strong correlation with the individualised area of 
overlap. Although the correlation for the SC max dose was 
slightly stronger for the uniform contraction, all other 
parameters showed an equivalent or stronger correlation with 
the area of overlap for the individualised contour than for 
the uniform contour. Furthermore, the uniform contour 
failed to show any correlation with the max dose to the BS. 
 
 
Conclusions: These preliminary results suggest that a simple 
tool, based on the individualised contour and area of overlap, 
can help predict dosimetric changes resulting from weight 
loss in HN VMAT patients. This could provide an objective 
assessment of weight loss during treatment, improving the 
workflow for HN ART, potentially acting as a trigger for plan 
adaptation. 
    
PO-0935   
Evaluation of deformable image registration methods for 
dose monitoring in head and neck adaptive radiotherapy 
B. Rigaud1, A. Simon1, J. Castelli2, M. Gobeli2, J.D. Ospina 
Arango1, G. Cazoulat1, O. Henry2, P. Haigron1, R. De 
Crevoisier2 
1INSERM U1099, Laboratoire Traitement du Signal et de 
l'Image, Rennes, France  
2INSERM U1099, Centre Eugene Marquis, Rennes, France  
